文献速递眼底病与葡萄膜炎

VISTA研究中接受玻璃体腔注射阿柏西普或激光治疗的糖尿病黄斑水肿患眼视网膜灌注状态的纵向变化

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
PubMed 文献 · Ophthalmology · 2019-04-01

VISTA研究的事后分析评估了糖尿病黄斑水肿(DME)患者接受玻璃体腔注射阿柏西普(IAI)2q4、2q8方案或激光治疗后视网膜灌注状态的变化。至第100周,激光组、2q4组和2q8组视网膜灌注改善的比例分别为14.6%、44.7%和40.0%,灌注恶化的比例分别为25.0%、9.0%和8.6%。

要点

  • VISTA研究事后分析纳入466例中心受累DME患者,随机分至激光组、IAI 2q4组或IAI 2q8组。
  • 第100周视网膜灌注改善比例:激光组14.6%,2q4组44.7%,2q8组40.0%。
  • 第100周视网膜灌注恶化比例:激光组25.0%,2q4组9.0%,2q8组8.6%。

核心结论

  • VISTA研究事后分析提示,规律IAI给药不仅可能减缓糖尿病视网膜病变相关的视网膜灌注恶化,还可能通过减少视网膜无灌注(RNP)区域在某些病例中改善视网膜灌注。

研究设计与样本

  • VISTA研究的事后分析,为双盲、随机、活性对照的3期试验。
  • VISTA研究随机分配466例患者至激光组、IAI 2 mg每4周一次(2q4)组或IAI 2 mg每8周一次(2q8,在5次每月剂量后)组。
  • 每例患者入组一只研究眼;通过荧光素血管造影评估视网膜灌注状态,由设盲的独立读片中心在基线及第24、52、72、100周评估以视神经乳头为交叉点的象限内视网膜无灌注(RNP)的存在与否。
  • 所有访视时评估视觉和解剖学结局;接受补救治疗的患者自补救治疗给药时起数据删失。

主要发现

  • 第100周时,激光对照组、2q4组和2q8组视网膜灌注改善(定义为RNP存在的象限总数较基线减少)的患眼比例分别为14.6%、44.7%和40.0%。
  • 第100周时,激光对照组、2q4组和2q8组视网膜灌注恶化(定义为RNP存在的象限总数较基线增加)的患眼比例分别为25.0%、9.0%和8.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate changes in retinal perfusion status with intravitreal aflibercept injection (IAI) and laser treatment in the phase 3 VISTA study of patients with diabetic macular edema (DME). DESIGN: Post hoc analysis of a double-masked, randomized, active-controlled, phase 3 trial. PARTICIPANTS: Patients with center-involved DME in the study eye. METHODS: VISTA randomized 466 patients to laser, IAI 2 mg every 4 weeks (2q4), or IAI 2 mg every 8 weeks after 5 monthly doses (2q8). One eye per patient was enrolled in the study. Retinal perfusion status was evaluated by fluorescein angiography based on the presence or absence of retinal nonperfusion (RNP) in quadrants intersecting at the optic nerve head by a masked independent reading center at weeks 24, 52, 72, and 100. Visual and anatomic outcomes were evaluated at all visits. In patients who received rescue treatment, data were censored from the time rescue treatment was given. MAIN OUTCOME MEASURES: Change in perfusion status from baseline through week 100. RESULTS: At week 100, the proportion of eyes with improvement in retinal perfusion (defined as a reduction from baseline in the total number of quadrants in which RNP is present) in the laser control, 2q4, and 2q8 groups was 14.6%, 44.7%, and 40.0%, respectively. The proportion of eyes that experienced worsening in retinal perfusion (defined as an increase from baseline in the total number of quadrants in which RNP is present) at week 100 in the laser control, 2q4, and 2q8 groups was 25.0%, 9.0%, and 8.6%, respectively. CONCLUSION: Post hoc analysis of the phase 3 VISTA study in patients with DME provides evidence that regular IAI dosing not only can slow worsening of retinal perfusion associated with diabetic retinopathy but also may be able to improve retinal perfusion in some cases by decreasing zones of RNP.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wykoff CC, Shah C, Dhoot D, et al. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study. Ophthalmology. 2019. PMID: 30946887. doi:10.1016/j.ophtha.2019.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。